Jupiter Life Lin
Jupiter Life Lin Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
2 of 4 strong
Not discussed on this call: order book.
The short version
Dombivli Hospital's patient footfall is gradually increasing month-on-month, ramping up as expected. Jupiter Life Line Hospitals expects steady growth primarily driven by ramp-up in newer hospitals like Dombivli, which is gradually increasing patient footfall and aiming to breakeven in its second year.
From Jupiter Life Lin's Q1 FY27 earnings-call transcript · updated 25 Aug 2026.
Revenue & Sales Performance
- Dombivli Hospital's patient footfall is gradually increasing month-on-month, ramping up as expected.
- Revenue growth for mature hospitals (Thane and Pune) expected mostly in line with inflationary price hikes; Pune may see slower growth as it approaches higher occupancy (~75%).
- Indore and Dombivli hospitals have room for faster revenue growth due to occupancy expansions.
- ARPOB (Average Revenue per Occupied Bed) growth driven by case mix improvement and pricing renegotiations; expected to grow higher than inflation initially for new units, later aligning with inflation.
- Overall growth expected around 13-16% for existing units, with Dombivli continuing its ramp-up.
- EBITDA breakeven for Dombivli expected in the second year of operation; current monthly EBITDA loss guidance INR 2-3 crores.
- Expansion plans ongoing with three projects to be delivered in next 5 years, focusing on Western India market.
Profitability & Margins
See what Jupiter Life Lin said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Capex for current and upcoming hospital projects is ongoing and detailed in the financial presentation; internal accruals and cash on hand are expected to cover the next few years of capex.
- Towards the end of the current capex cycle, some additional debt may be explored but will remain within a board-imposed ceiling of 3x EBITDA.
- Jupiter recently acquired a company to set up an IV fluids manufacturing unit as a backward integration for its pharmacy subsidiary, aiming for cost management and margin improvement.
- The IV fluids manufacturing plant involves a capex of around INR 35-40 crores including infrastructure.
- The focus remains on hospital expansion primarily in Western India, with three ongoing projects targeted for completion within five years.
- The strategy is to add capacity incrementally as occupancy reaches certain thresholds to manage margin compression and avoid EBITDA losses after initial ramp-up.
Top-ranked in Healthcare Services
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Jupiter Life Lin said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Jupiter Life Lin — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹388 Cr, net profit ₹50 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Jupiter Life Lin's management said in earlier quarters
Others in Healthcare Services this season
- Manipal Health Enterprises Ltd (Q1 FY27)
Volume-led growth with inpatient (IP) volumes up 39% and outpatient (OP) volumes up 26% year-on-year. Key concall takeaways from Manipal Health Enterprises…
- Fortis Healthcare Ltd (Q1 FY27)
IHH plans to increase its stake in Fortis to over 50% within 3-5 years, supporting long-term strategic growth. Key concall takeaways from Fortis Healthcare…
- Metropolis Healthcare Ltd (Q1 FY27)
East India currently 6%, with limited investment so far; future investments may increase contribution. Key concall takeaways from Metropolis Healthcare Ltd's…
- Apollo Hospitals Enterprise Ltd (Q1 FY27)
IP volume growth for established units guided at roughly 7% to 8%. Key concall takeaways from Apollo Hospitals Enterprise Ltd's Q1 FY27 earnings call — and how…
Frequently Asked Questions
What were Jupiter Life Lin Q1 FY27 results?
Dombivli Hospital's patient footfall is gradually increasing month-on-month, ramping up as expected. Jupiter Life Line Hospitals expects steady growth primarily driven by ramp-up in newer hospitals like Dombivli, which is gradually increasing patient footfall and aiming to breakeven in its second year.
What is Jupiter Life Lin share price analysis?
Jupiter Life Lin currently shows a below-average growth signal. The stock trades at a P/E of 53.1 with a market cap of ₹10,155 Cr. Investors should review the full earnings analysis for detailed insights.
Is Jupiter Life Lin planning capital expenditure?
Capex for current and upcoming hospital projects is ongoing and detailed in the financial presentation; internal accruals and cash on hand are expected to cover the next few years of capex.
Keep Jupiter Life Lin on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.